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Whether lymphovascular invasion (LVI) is an independent prognostic factor in prostate 
cancer is still controversial. We retrospectively investigated its predictive role in disease 
progression following radical prostatectomy. The histological sections of radical 
prostatectomies from 71 clinically localized, prostatic adenocarcinoma patients were 
reviewed for LVI. Pre- and postoperative follow-up data were collected. LVI was identified 
in 15.5% of cases. Univariate analysis showed a significant association between LVI and 
advanced pathological stage, higher Gleason score, positive surgical margins, 
extraprostatic extension, seminal vesicle invasion, and lymph node metastasis (each p < 
0.05). Multivariate analyses pointed to vascular involvement as a strong and independent 
predictor for PSA failure (p = 0.023), and reduced biochemical progression-free survival 
(p = 0.019). LVI in radical prostatectomy is an adverse prognostic finding that must be 
recorded in the pathology report.  
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INTRODUCTION 
Prostate carcinoma is a heterogeneous disease and its prognosis is highly variable. Many researchers 
focus on investigating significant markers of prognostic significance. The association of vascular invasion 
with unfavorable outcome has been known for a long time. However, the question is still whether or not it 
adds more beyond other commonly used standard parameters. Not all studies have found independent 
significance of lymphovascular invasion (LVI) in multivariant analysis. The Association of Directors of 
Anatomic and Surgical Pathology and the College American Pathologists (CAP) require that LVI is 
reported in transrectal needle biopsies or transurethral resection of prostate; however, reporting it on 
radical prostatectomy is not addressed[1,2]. On the other hand, the Association of Anatomic and Surgical 
Pathology recently assembled and updated the CAP protocol to comply with the American College of 
Surgery Commission on Cancer (COC) requirements[3]. In their checklist, a record of angiolymphatic 
invasion is required in pathology reports for radical prostatectomy. 
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Studies that issue the role of vascular invasion in prostate carcinoma are few. The reported incidence 
of LVI varies widely from 5 to 53%[4,5,6,7,8,9,10,11,12,13,14,15,16,17]. This wide range possibly 
results from difficulty in its recognition, deficiency of standardized histologic criteria, and variations in 
the study population. In a recent article, Cheng et al. showed a significant association between LVI and 
adverse pathologic features, including advanced pathological stage, higher Gleason score, positive 
surgical margins, extraprostatic extension, seminal vesicle invasion, lymph node metastasis, and 
perineural invasion, as well as higher preoperative serum prostate specific antigen (PSA)[15]. They 
determined LVI as an independent predictor of PSA and cancer-specific survival. The aim of our study is 
to investigate the prevalence and role of LVI as a prognostic indicator in our series of clinically localized, 
prostate carcinoma treated with radical prostatectomy.  
METHODS 
Seventy-one clinically localized, prostate cancer patients treated with radical prostatectomy (RP) were 
included in this study. The RPs were done by one surgeon at the same academic institution between 1992 
and 2001. Sixty-nine cases had pelvic lymphadenectomy. None of the patients had received adjuvant 
antitumor therapy before surgery. Pre- and postoperative data were collected on all patients from the 
hospital charts. Clinical follow-up data were available on 67 cases. The patients were postoperatively 
followed up for an average of 65 months (median, 54 months; range, 4–145 months). The serum levels of 
PSA were determined at 3-month intervals after RP for the first year and at 6-month intervals thereafter. 
Biochemical failure was determined by a constant or increasing PSA level of >0.2 ng/ml on two 
successive measurements. 
All slides for each case were retrieved from the pathology archives and were reviewed by a single 
pathologist (D.E.B.). Prognostically well-established pathological parameters, including Gleason score, 
status of extraprostatic extension, seminal vesicle invasion, surgical margins, lymph node metastases, and 
pathologic stage (pT), in addition to the presence of LVI, were noted. Tumor volume was estimated by 
simple eye-balling. In the evaluation of vascular involvement, care was taken to exclude artifacts due to 
retraction or mechanical displacement of tumor cells into lumen by blade (pseudoemboli), tumor within 
prostatic ducts and within perineural spaces. For the equivocal cases, LVI was confirmed for the presence 
of endothelium using antibody to CD31 (Clone CJ70A, Dako, Copenhagen, Denmark). Differentiating 
blood vessels from lymphatics was not attempted since, for practical purposes, either lymphatic or venous 
involvement implies ultimate reach to the circulatory system. 
Statistical analyses between groups were performed using Fisher’s exact and chi-square tests for 
categorical variables and the Mann-Whitney U-test for continuous variables. Survival analyses, including 
time to PSA relapse or biochemical progression-free survival (PFS), were performed with Kaplan-Meier 
methods. Logistic regression and Cox proportional hazard models were used to carry out multivariate 
tests; p ≤ 0.05 was taken to indicate statistical significance. 
RESULTS 
Ages of the patients varied between 48 and 75 (average, 62; median, 63). PSAs at diagnosis ranged from 
1.3 to 41.5 ng/ml (mean, 11.5 ng/ml). Pelvic lymph node metastasis was detected in five patients (one 
lymph node in two, two lymph nodes in two, and three lymph nodes in one patient). At a mean of 41 
months after surgery, 22 cases had biochemical progression. Among them, eight patients experienced 
local recurrence of the tumor; one man developed distant metastases and died of the disease. 
LVI was identified in 15.5% of patients (11/71). It was seen intratumoral in 6/11, at the periphery of 
the tumor in 2/11, both intra- and peritumoral in 1/11, and at a distant site from the tumor in 2/11 cases 
(Fig. 1). Average number of foci was 6.  





FIGURE 1. Intravascular neoplastic cells. (A) Inside the tumor (H-E ×400); (B) at the periphery of the tumor (H-E ×200); (C) distant from the 
tumor (H-E ×400). 
Characteristics of the patients with LVI were summarized in Table 1. Age and preoperative PSA level 
did not differ between LVI-positive and -negative groups. A significant association was found between 
LVI with higher Gleason score, extracapsular tumor extension, positive surgical margins, seminal vesicle 
invasion, pathological stage, and lymph node metastases on univariate analyses (all p < 0.05) (Table 2) 
(Figs. 2 and 3). 





Among 11 patients with LVI, 10 had follow-up data. Nine out of 10 had recurrent disease (seven 
isolated biochemical failure, two local relapse, and one distant metastasis). LVI was the strong independent 
predictor for PSA failure in multivariant analysis when taken into account with grade, pT, lymph node 
involvement, age at diagnosis, preoperative PSA levels, and positive margins (p = 0.023, logistic regression 
model). Gleason score was the other equally powerful independent variable of recurrence (p = 0.023). 
In Cox regression analysis, LVI, pathological stage, and Gleason sum were the factors that 
determined the time to PSA failure (significance values 0.019, 0.027, and 0.049, respectively). The 
average time to biochemical PFS was significantly shorter for patients with LVI compared with patients 
without LVI (46.5 vs. 79 months, respectively). At 5 years, the PFS rate was 70% for patients without 
LVI, compared with 20% for patients with LVI (Fig. 4). 






Pathology has assumed an important role in the assessment of adenocarcinomas of the prostate during the 
last years. Postoperative data from the pathologic workup of RPs, such as tumor histology, differentiation, 
volume, pathological stage, margin, and lymph node status, give important information for the prediction 
of tumor outcome. The weight of evidence suggests that the presence of LVI in prostate cancer is 
indicative of unfavorable prognosis. However, debate continues on the role of LVI as an independent 
prognosticator.  















1 60 13.7 7 Present No (–) 3a Present Yes 36 Absent 
2 60 41.5 7 Present Yes (+) 3b Present Yes 26 Absent 
3 71 7.2 8 Present Yes (+) 3b Absent Yes 29 Present 
4 51 8.9 9 Present Yes (+) 3b Absent Yes 3 Absent 
5 62 25.0 9 Present No (+) 3a Absent Yes 35 Absent 
6 69 24.1 9 Present Yes (+) 3b Present Yes 24 Absent 
7 65 28.0 7 Present No (–) 3a Absent Yes 31 Absent 
8 59 19.4 7 Present Yes (+) 3b Absent Yes 84 Absent 
9 72 11.0 7 Present Yes (+) 3b Present Yes 21 Absent 
10* 60 8.2 7 Present Yes (+) 3b Absent NA NA NA 
11 67 8.5 7 Present No (–) 3a Absent No 57 Absent 
* Clinical follow-up data not available for this case. NA, not applicable. 
TABLE 2 
Pathological Parameters and PSA Relapse According to Vascular Invasion 






6 18 (100%) 0 (0%) 
7 30 (81.1%) 7 (18.9%) 
Gleason score 
>8 12 (75%) 4 (25%) 
0.026 
Absent 23 (100%) 0 (0%) Extraprostatic extension 
Present 36 (76%) 11 (24%) 
0.002 
Absent 49 (91.5%) 4 (7.5%) Seminal vesicle invasion 
Present 11 (61%) 7 (39%) 
0.002 
Absent 35 (92%) 3 (8%) Positive surgical margins 
Present 24 (75%) 8 (25%) 
0.048 
pT2 23 (100%) 0 (0%) 
pT3a 25 (83.3%) 5 (16.7%) 
Pathological stage 
pT3b 11 (61.1%) 7 (38.9%) 
0,001 
Absent 57 (89%) 7 (11%) Lymph node metastasis 
Present 1 (20%) 4 (75%) 
0.001 
Absent 44 (97.7%) 1 (2.3%) PSA relapse 
Present 13 (59%) 9 (41%) 
0.001 
Note: n, number of cases evaluable. 
Findings in our clinically localized prostate cancer cohort indicate that LVI has a positive correlation 
with Gleason score, extraprostatic extension, seminal vesicle invasion, positive surgical margins, and 
pathological stage, in addition to lymph node metastasis. All patients with LVI have Gleason score 7 or 
higher, and pathological stage of pT3a or T3b, with 64% seminal vesicle invasion. Seventy-three percent  




FIGURE 2. A neoplastic gland in a vascular space (A). The same tumor showing extraprostatic extension with positive surgical margins (B) and 
seminal vesicle invasion (C). (A: H-E ×400, B: H-E ×200; C: H-E ×200). 
reveal positive surgical margins. Likewise, Loeb et al. reported significant association between LVI and 
tumor grade, tumor stage, tumor volume, and lymph node metastasis[16]. They additionally demonstrated 
statistically significant differences in rates of biochemical progression and 7-year PFS between patients 
with and without LVI. However, they could not confirm these findings in multivariate analysis. Their 
incidence of LVI is low (7%). An association between LVI and adverse outcomes, such as distant 
metastases, death, shorter PSA doubling time before salvage radiotherapy, and biochemical progression 
after salvage radiotherapy, has also been shown by Shariat et al. on univariate analysis[14]. Again, they 
have not observed LVI as an independent predictor of biochemical progression on multivariant analysis. 




FIGURE 3. (A) LVI adjacent to a high-grade prostate carcinoma (H-E ×400). (B) Lymph node metastasis from the same tumor (H-E ×400). 
Results of the studies that assess the prognostic value of a marker related to pathology depend highly 
on the criteria used to define the marker and on the selection of cohort. Variations in specimen handling 
by different laboratories and interobserver variability between pathologists further complicate the issue 
and lead to irreproducibility. Although case number can be considered limited, re-evaluation of pathology 
slides by a single pathologist who is expert in the field of genitourinary pathology, application of 
immunohistochemistry on equivocal or difficult conditions for confirmation of LVI, and relatively long 
mean follow-up terms are the features that support reliability in the present study. 




FIGURE 4. Biochemical PFS curves of the patients in regard to LVI. 
In addition to a close relationship with known markers of poor prognosis, the high rate of positive 
LVI strongly correlates with increased biochemical recurrence in our series. On multivariate analysis, 
LVI and Gleason score values are independent, high-risk factors for biochemical failure. So LVI, as well 
as tumor grade, appears as predictive of PSA relapse in clinically localized prostate cancer patients who 
have RP. Survival analysis with Kaplan-Meier curves points to worse prognostic indication by LVI. We 
have detected a significant difference in biochemical PFS between patients with and without LVI. As 
expected, pathological stage and Gleason score are the other significant effectors of PSA relapse-free 
survival. Similarly, Babaian et al. found that pathologic category and LVI are the only significant 
independent predictors of progression in 265 RP patients[11]. Herman et al. studied stage pT3N0 disease, 
and observed that LVI is a significant predictor of progression on both univariate and multivariate 
analyses[8]. Five-year biochemical-free survival has been reported as 87.3% for patients with no LVI and 
38.3% with LVI on the RP specimens (p < 0.001) by May et al.[17]. 
Consequently, RP specimens should be routinely evaluated for the presence of LVI. The clinical use 
of multivariate nomograms has provided a more accurate and relevant individualized prediction of 
survival for improved patient counseling and treatment. LVI is a pathological variable that might help 
clinicians to subclassify patients with an adverse risk of tumor progression and can be included in 
postoperative nomograms with other histological variables to select the group that might benefit from 
adjuvant therapies. 
LVI by tumor cells is histologically evident in approximately 15.5% of prostatic carcinomas and is 
present in close to 10% of cases with pathologically negative lymph nodes in our series consisting of 
clinically localized cases. LVI is independently indicative of unfavorable prognosis in the prostate cancer 
as manifested by increased PSA failure and reduced biochemical PFS. It is for this reason that LVI should 
be routinely included in the evaluation and reporting of all prostate cancers.  
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